Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Prof David Currow - Flinders University, Adelaide, Australia
New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Prof David Currow - Flinders University, Adelaide, Australia )
27 Sep 2014

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA
Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )
23 Sep 2014

Current treatment options in mRCC

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA
Current treatment options in mRCC ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )
23 Sep 2014

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán
Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )
23 Sep 2014

The evolving treatment landscape for HER2-positive metastatic breast cancer

Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium
The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )
18 Sep 2014

Navigating current treatment options for HER2-positive MBC: Patient journey 1

Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria
Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )
18 Sep 2014

Overview of skin cancer treatments, past, present and future

Prof John Hawk - President of the World Congress on Cancers of the Skin 2014
Overview of skin cancer treatments, past, present and future ( Prof John Hawk - President of the World Congress on Cancers of the Skin 2014 )
11 Sep 2014

Advances in CLL: Expert panel Discussion

Prof Robin Foà ; Prof Clemens Wendtner; Dr Francesc Bosch; Prof Florence Cymbalista
Advances in CLL: Expert panel Discussion ( Prof Robin Foà ; Prof Clemens Wendtner; Dr Francesc Bosch; Prof Florence Cymbalista )
11 Sep 2014

Emerging treatments in CLL: Expert Discussion

Prof Robin Foà and Prof Peter Hillmen
Emerging treatments in CLL: Expert Discussion ( Prof Robin Foà and Prof Peter Hillmen )
11 Sep 2014

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction

Prof Aristoteles Giagounidis - St John’s Hospital, Duisburg, Germany
Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction ( Prof Aristoteles Giagounidis - St John’s Hospital, Duisburg, Germany )
4 Sep 2014

Hot topic: B-cell depletion in adult chronic ITP

Dr Francesco Zaja - University of Udine, Udine, Italy
Hot topic: B-cell depletion in adult chronic ITP ( Dr Francesco Zaja - University of Udine, Udine, Italy )
4 Sep 2014